
Advances in Cancer Research
Description
Key Features
- Provides information on cancer research
- Outstanding and original reviews
- Suitable for researchers and students
Readership
Table of Contents
- 1. Unravelling the Complexity and Functions of MTA Coregulators in Human Cancer
Da-Qiang Li, Rakesh Kumar
2. Examination of Epigenetic and other Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through Integrated Analyses of Public Genomic Datasets
Manny D. Bacolod , Swadesh K. Das , Upneet K. Sokhi, Steven Bradley , David A. Fenstermacher , Maurizio Pellecchia, Luni Emdad, Devanand Sarkar and Paul B. Fisher
3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer
Sarah K. Martin and Natasha Kyprianou
4. Stem Cell-Based Therapies for Cancer
Deepak Bhere and Khalid Shah
5. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance
Nathan G. Dolloff
6. Influence of Bone Marrow Microenvironment on Leukemic Stem Cells: Breaking up an Intimate Relationship
Puneet Agarwal and Ravi Bhatia
7. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-negative Breast Cancer: Ligand-mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting
Carly Bess Williams, Adam C. Soloff, Stephen P. Ethier, and Elizabeth S. Yeh
8. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma
Bridget A. Quinn, Nathaniel A. Lee, Timothy P. Kegelman, Praveen Bhoopathi, Luni Emdad, Swadesh K. Das, Maurizio Pellecchia, Devanand Sarkar and Paul B. Fisher
Product details
- No. of pages: 326
- Language: English
- Copyright: © Academic Press 2015
- Published: June 18, 2015
- Imprint: Academic Press
- eBook ISBN: 9780128029428
- Hardcover ISBN: 9780128029206
About the Serial Volume Editors
Kenneth Tew

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Affiliations and Expertise
Paul B. Fisher
